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ABSTRACT
Purpose: Apicidin, a histone deacetylase inhibitor, is a
novel cyclic tetrapeptide that exhibits potent antiprolifera-
tive activity against various cancer cell lines. The aim of this
study was to examine the potential of apicidin to induce
apoptosis in human Bcr-Abl-positive leukemia cells and to
assess the mechanism of apicidin-induced apoptosis.
Experimental Design: Cells were exposed to various
concentrations of apicidin for 2–72 h, after which the levels
of apoptosis, histone acetylation, mitochondrial damage,
caspase activation, and Bcr-Abl expression were assessed.
Results: Apicidin induced apoptosis in K562 cells in a
concentration- and time-dependent manner. Similarly, api-
cidin notably induced the apoptosis in the primary leukemic
blasts obtained from chronic myelogenous leukemia patients
in blast crisis. The acetylated histone H4 levels increased in
a concentration-dependent manner in the K562 cells. How-
ever, the timing of cell death caused by apicidin did not
exactly correlate with the histone deacetylase inhibitory ef-
fect. The disruption of the mitochondrial membrane poten-
tial, cytochrome c release into the cytosol, and the mitochon-
drial Bax translocation were notably demonstrated after the
apicidin treatment. Apicidin induced the proteolytic cleav-
age of procaspase-9, -3, -8, and poly(ADP-ribose) polymer-
ase. Pretreatment of the K562 cells with the caspase-3
inhibitor, DEVD-CHO, completely inhibited the apicidin-
induced apoptosis, suggesting that apicidin-induced apo-
ptosis was caspase-dependent. The Fas/Fas ligand death
receptor pathway was not involved in the apicidin-mediated
apoptosis in K562 cells. Pretreatment of the cells with the
caspase-9 inhibitor LEHD-fmk abrogated the apicidin-
induced cleavage of procaspase-3, -8, and poly(ADP-ribose)
polymerase. The p210 Bcr-Abl protein levels were notably
decreased after the apicidin treatment, with near complete
loss after 48 h. Reverse transcription-PCR assay demon-
strated that the Bcr-Abl mRNA level was also remarkably
decreased in a time-dependent manner.
Conclusions: These results indicate that apicidin effec-
tively induces the apoptosis of Bcr-Abl-positive leukemia
cells through the activation of the mitochondrial pathway-
dependent caspase cascades. The down-regulation of Bcr-
Abl mRNA might also be one of the mechanisms implicated
in the apicidin-mediated apoptosis in the K562 cells. This
study provides the rationale to additionally investigate api-
cidin as a potential therapeutic agent for the drug-resistant
Bcr-Abl-positive leukemia cells.
INTRODUCTION
The acetylation and deacetylation of the histones of the
core proteins of the nucleosomes in chromatin play an important
role in regulating gene expression (1). Transcriptionally active
genes are associated with the highly acetylated core histones. In
contrast, histone deacetylation is associated with gene silencing
and transcriptional repression (2, 3). The acetylation status of
the histones is controlled by the activities of two enzyme fam-
ilies, histone acetyltransferases and HDAC3 (4, 5). The dereg-
ulation of histone acetylase and HDAC has been suggested to
play a causative role in the development of cancer by changing
the expression pattern of a variety of genes, such as oncogenes
and tumor suppressor genes (6, 7). Gene silencing by the HDAC
complexes is an important mechanism in the development of
some types of leukemia, most notably APL (8). The two fusion
proteins in APL, promyelocytic leukemia-retinoic acid receptor
, and promyelocytic leukemia zinc finger-retinoic acid receptor
, recruit the nuclear corepressor-HDAC complexes. This leads
to histone deacetylation and transcriptional repression, which
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results in a maturational block in the myeloid cell lineage (8, 9).
There is also evidence implicating aberrant HDAC-mediated
transcriptional repression in some forms of AML. The AML-
ETO fusion protein, often demonstrated in the M2 subtype of
AML with t(8;21) translocation, is a potent transcriptional re-
pressor by recruiting HDAC to the transcriptional repressor
complex (10, 11).
In recent years, an increasing number of structurally di-
verse HDAC inhibitors, which accumulate the acetylated his-
tones in the nucleus, have been demonstrated to induce growth
arrest, differentiation, and apoptosis of tumor cells both in vitro
and in vivo (11–16). Accumulating evidence suggests that the
induction of histone hyperacetylation by the HDAC inhibitors is
responsible for the antiproliferative activity along with the re-
versal of the neoplastic characteristics through the selective
transcriptional activation of certain genes, which play important
roles in the cell cycle and cell morphology (5–7, 14, 17). The
effect of HDAC inhibition and its potential clinical utilization
have been reported in AML (18–20). Treatment with an HDAC
inhibitor can relieve the ETO-mediated transcriptional repres-
sion and induce AML-ETO cell differentiation (11). It was
reported that sodium phenylbutyrate, an HDAC inhibitor, in-
duced complete remission in an APL patient with all-trans
retinoic acid resistance (20). The antileukemia effects of the
HDAC inhibitors in APL were caused primarily by the initiation
of leukemic cell differentiation, which is similar to the proposed
all-trans retinoic acid effect (21, 22). However, a recent study
demonstrated that the HDAC inhibitors can induce caspase-
dependent apoptosis and the down-regulation of daxx in APL
cells with t(15;17; Ref. 23). Apoptosis was also demonstrated in
lymphoblasts and myelomonocytic leukemia cells after treat-
ment with HDAC inhibitors (24, 25). This suggests the potential
utility of HDAC inhibitors in treating leukemic disorders.
K562 is a CML cell line expressing a p210 Bcr-Abl fusion
protein. Previous studies have shown that this cell line is par-
ticularly resistant to cell death via apoptosis, irrespective of the
stimuli (26, 27). STI571, a new Abl tyrosine kinase inhibitor,
has been shown to inhibit the growth of Bcr-Abl-positive leu-
kemia cells in vitro (28) and is highly effective in treating the
early stages of CML (29). However, the emergence of STI571
resistance in CML patients, who were initially responsive to this
agent (30, 31), has prompted the search for an alternative
approach to treating this disease using HDAC inhibitors.
Apicidin is a novel HDAC inhibitor with a potent broad
spectrum of antiproliferative activity against various cancer cell
lines (14, 24). It was reported that apicidin arrests human cancer
cell growth by selectively inducing p21WAF/Cip1. Apicidin has
been demonstrated to potentially induce HL-60 leukemia cell
apoptosis through the selective induction of the Fas/Fas ligand,
resulting in the mitochondrial release of cytochrome c, and the
subsequent activation of caspase-9 and caspase-3 (32). If the
apicidin treatment can effectively induce Bcr-Abl-positive CML
cell apoptosis and its apoptosis-inducing mechanisms be under-
stood, the development of novel therapeutic approaches for
treating Bcr-Abl-positive leukemia, such as CML and a subset
of ALL, is expected. In this report, apicidin is demonstrated to
induce the apoptosis of Bcr-Abl-positive leukemia cells through
the activation of a mitochondria-dependent caspase cascade.
Because apicidin induces the cell death in apoptosis-resistant
Bcr-Abl-positive leukemia cells efficiently, its potential as a
therapeutic agent should be additionally validated.
MATERIALS AND METHODS
Cells and Culture Condition. The K562 cell line was
obtained from the American Type Culture Collection (Manas-
sas, VA). The cells were grown in RPMI 1640 (Life Technol-
ogies, Inc. Grand Island, NY) supplemented with 10% (v/v)
heat-inactivated fetal bovine serum (HyClone Laboratories, Lo-
gan, UT), 1% penicillin/streptomycin, and 2 mM L-glutamine
(Life Technologies, Inc.). The cultures were maintained in a
humidified atmosphere of 5% CO2 and 95% air at 37°C. In all
of the experiments, 2  106 cells/ml of the growing cells were
placed in each well of a six-well plate containing 3-ml RPMI
1640 plus 10% fetal bovine serum and were exposed to apicidin
for the indicated time intervals. Two days before commencing
the STI571 (Gleevec; Novartis, Basel, Switzerland), the periph-
eral blood leukemic blasts were prepared from 4 CML patients
in blast crisis, who provided informed consent. The peripheral
blood was sedimented on Ficoll-Hypaque (Pharmacia Biotech,
Uppsala, Sweden) density gradient. After washing the cells
collected from the upper interface, T-cell depletion was per-
formed using a high gradient magnetic cell separation system/
anti-CD3 monoclonal antibody (Miltenyi Biotech, Auburn, CA)
according to the manufacturer’s instructions. A morphological
evaluation indicated that 95% of the isolated cells were leu-
kemic blasts.
Reagents and Antibodies. Apicidin [cyclo(N-O-methyl-
L-tryptophanyl-L-isoleucinyl-D-pipecolinyl-L-2-amino-8-oxo-
decanoyl)] was purchased from Calbiochem (San Diego, CA). A
stock solution (1 mM) in sterile DMSO (Sigma-Aldrich, St.
Louis, MO) was stored at 80°C for no more than 3 months.
The final DMSO concentration in the cultures was kept at 0.1%,
which is a concentration that is nontoxic to the cells. A
caspase-3 inhibitor, DEVD-CHO (Calbiochem), and a caspase-9
inhibitor, LEHD-fmk (Calbiochem), were dissolved in DMSO,
and stored at 70°C until needed. The NOK-1 monoclonal
antibody that interferes with the Fas-Fas ligand interaction and
inhibits Fas signaling was obtained from PharMingen (San
Diego). The antibodies against procaspase-3, procaspase-8, and
procaspase-9 were obtained from PharMingen. The antibodies
against the cleaved caspase-3, cleaved caspase-8, cleaved
caspase-9, cytochrome c, Fas ligand, Bax, and PARP were
purchased from Cell Signaling Technology (Beverly, MA). The
antibodies against Bcl-XL, Bcl-2, c-Abl, and Fas were obtained
from Santa Cruz Biotechnology Inc (Santa Cruz, CA). The
antibodies against histone H4, -tubulin, and acetyl-histone H4
were purchased from Upstate Biotechnology Incorporated (Lake
Placid, NY).
Annexin V Staining. The Annexin V assays were per-
formed according to the manufacture’s protocol (PharMingen).
Briefly, the cultured cells were collected, washed with binding
buffer, and incubated in 200 l of a binding buffer containing 5
l of Annexin-V-FITC. The nuclei were counterstained with
PI. The percentage of apoptotic cells was determined using
FACSCalibur flow cytometer (Becton Dickinson Immunocy-
tometry Systems, San Jose, CA).
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Cell Cycle Analysis. The cells were washed twice with
PBS and fixed with 70% ethanol/PBS. They were then treated
with 0.5 mg/ml RNase (Sigma) in PBS with 0.1% saponin, and
incubated at 37°C for 30 min before staining with 20 g/ml PI
for 30 min at 4°C. The cells (1  106) were then analyzed for
their DNA content using a FACSCalibur flow cytometer
equipped with CellQuest software (Becton Dickinson Immuno-
cytometry Systems).
DNA Fragmentation Assay. The cell pellets (1  106
cells) were resuspended in 500 l of a lysis buffer [0.5% Triton
X-100, 10 mM EDTA, and 10 mM Tris-HCl (pH 8.0)] at room
temperature for 15 min and centrifuged at 16,000  g for 10
min. The DNA was then extracted twice with phenol:chloroform
(1:1), precipitated with ethanol, and resuspended in a Tris/
EDTA buffer [10 mM Tris-HCl (pH 8.0) and 1 mM EDTA]. The
DNA was analyzed after being separated by 1.5% agarose gel
electrophoresis.
Assessment of Loss of MMP. The MMP was monitored
using DiOC6 as described previously (33). For each condition,
4  105 cells were incubated for 15 min at 37°C in 1 ml of 40
nM DiOC6 (Calbiochem) and subsequently analyzed using a
FACSCalibur flow cytometer and CellQuest software. The con-
trol experiments documenting the loss of MMP were performed
by exposing the cells to 5 M of carbamoyl cyanide m-chloro-
phenylhydrazone (Sigma), which is an uncoupling agent that
abolishes the MMP.
Histone Isolation and Immunodetection of Acetylated
Histone H4. The histones were isolated from the K562 cells
after treating them with apicidin for the indicated times using
the established techniques (14). The samples were then resus-
pended in a Laemmli sample buffer for 3 min and subjected to
15% SDS-PAGE to determine the acetylated histone H4 levels.
Preparation of Mitochondria and Cytosolic Fractions.
The K562 cells were harvested and rinsed with ice-cold PBS,
and the cell pellets were resuspended in 300 l of buffer A [20
mM HEPES-KOH (pH 7.5), 10 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, and 1 mM DTT] containing 250 mM sucrose and the
proteinase inhibitors. After homogenization, the unbroken cells,
a sample of the large plasma membrane, and the nuclei were
removed by centrifugation at 1,000  g for 1 min at 4°C. The
supernatant was then centrifuged at 10,000  g for 20 min at
4°C. The pellet fraction containing the mitochondria was dis-
solved in 50 l of the TNC buffer [10 mM Tris acetate (pH 8.0),
0.5% NP40, and 5 mM CaCl2]. The supernatant was additionally
centrifuged at 50,000  g for 2 h to obtain the cytosol, which
was immediately subjected to Western blot analysis.
Western Blot Analysis. After the treatment, whole cell
pellets (1  107 cells/condition) were washed twice in PBS,
resuspended in 50 l of PBS, lysed by adding 50 l of a 2 
Laemmli buffer [1 30 mM Tris-base (pH 6.8), 2% SDS, 2.88
mM 	-mercaptoethanol, and 10% glycerol], and briefly soni-
cated. The homogenates were quantified using a Coomassie
protein assay reagent (Pierce, Rockford, IL). Equal amounts of
protein (20 g) were separated by SDS-PAGE and electro-
blotted to nitrocellulose. The blots were stained in 0.1% amido
black and destained in 5% acetic acid to ensure the transfer and
equal loading. After blocking in PBS-T (0.05%) and 5% milk
for 1 h at 22°C, the blots were incubated in a fresh blocking
solution with an appropriate dilution of the primary antibodies
for 4 h at 22°C. The blots were washed 3  5 min in PBS-T and
then incubated with a 1:2000 dilution of horseradish peroxidase-
conjugated secondary antibody (Bio-Rad Laboratories, Hercu-
les, CA) for 1 h at 22°C. After washing four times in TBST, the
reactive proteins were visualized using an enhanced chemilu-
minescence detection system (Amersham Biosciences, Piscat-
away, NJ).
RT-PCR Analysis. The total cellular RNA was isolated
from the apicidin-treated cells using an RNeasy mini kit (Quiagen,
Hilden, Germany). Using equal amounts of the RNA from each
time point, the cDNA was synthesized using Moloney murine
leukemia virus reverse transcriptase (Perkin-Elmer, NJ). A two-
step nested PCR procedure was performed using three sets of
primers. The primer sets used for the first RT-PCR were: B1
5
-GAAGTGTTTCAGAAGCTTCTCC-3
; B3 5
-ACCATCGT-
GGGCGTCCGCAAGA-3
; and A3 5
-TGATTATAGCCTAA-
GACCCGGA-3
. The primer sets used for the nested PCR were:
A4 5
-ATCTCCACTGGCCACAAAATCAT. ACA-3
; B2 5
-
TGGAGCTGCAGATGCTGACCAACTCG-3
; and B4 5
-AG-
ATCTGGCCCA ACGATGGCGAGGGC-3
. Gel electrophoresis
and ethidium bromide staining was used to visualize the PCR
products
RESULTS
Induction of Apoptosis in Bcr-Abl-Positive Leukemia
Cells by Apicidin. This study demonstrated that apicidin in-
duced apoptosis in the K562 cells in a concentration- and
time-dependent manner. As shown in Fig. 1A, treating the K562
cells with 0.1 M apicidin for 72 h caused only a slight increase
in the proportion of apoptotic cells. However, increasing the
apicidin concentration (1.0–20 M) for 48–72 h resulted in a
sharp increase in the proportion of apoptotic cells, suggesting
that cell death occurred in a dose-dependent manner. When the
K562 cells were exposed to 2.5 M apicidin, the proportion of
apoptotic cells increased in a time-dependent manner. Almost
90% of the cell population underwent apoptosis after 72 h,
compared with10% of the control (0.1% DMSO-treated) cells
(Fig. 1A). The cells treated with apicidin showed the typical
apoptotic features such as cell shrinkage, chromatin condensa-
tion, and nuclear fragmentation (data not shown). An analysis of
the DNA fragmentation showed an increase in cellular DNA
degradation in a time-dependent manner (Fig. 1B), which is
consistent with the increased proportion of apoptotic cells. Sim-
ilar results were obtained when the apoptosis was monitored by
cell cycle analysis. Exposure to 2.5 M apicidin for 8 h had no
remarkable effect on the cell cycle distribution of the K562
cells. However, the apicidin treatment for 24–72 h resulted in a
progressive increase in the sub-G1 cell fraction (Fig. 1C). Sim-
ilarly, the apicidin treatment remarkably increased the levels of
apoptosis in the primary leukemic blasts obtained from the 4
patients with CML in blast crisis in a time-dependent manner
(Fig. 1D).
Effects of Apicidin on Histone Acetylation. The ef-
fects of apicidin on the intracellular level of histone H4 was
analyzed to additionally examine the relationship between
cell death and histone acetylation in the K562 cells. The cells
were treated with various apicidin concentrations for the
indicated times, and the histones extracted from the nuclei
5020 Apicidin-Induced K562 Cell Apoptosis
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were subjected to Western blot analysis. As shown in Fig. 2A,
the amount of histone H4 acetylation increased in a concen-
tration-dependent manner, reaching a maximum level at 2.5
M apicidin, which remained at this level at higher concen-
trations. Apicidin did not cause any change in the amount of
histone H4 (Fig. 2A). The amount of histone H4 acetylation
notably increased as early as 2 h after the treatment with 2.5
M of apicidin, with a remarkable increase in the acetylated
histone H4 levels after 24 h (Fig. 2B).
Disruption of MMP by Apicidin. The amount of MMP
disruption was assessed after the apicidin treatment by meas-
uring the mitochondrial uptake of a membrane potential-sensi-
tive dye, DiOC6, in the K562 cells. When the cells were treated
with 2.5 M apicidin, the population that lost MMP was 32.8%
at 16 h and 51.7% at 24 h (Fig. 3A). This suggests that an
apoptosis-inducing mechanism triggered by apicidin operates
via the mitochondria in the K562 cells.
Effect of Apicidin on Cytochrome c Release and Bax
Translocation. Fig. 3B shows the time-dependent release of
cytochrome c from the mitochondria into the cytosol after being
exposed to 2.5 M apicidin. Increased levels of cytochrome c
were notably detected in the cytosol after 16 h, reaching the
maximum levels after 24 h of treatment. Cytochrome c in the
mitochondrial fraction decreased in parallel after 16 h of apici-
din treatment. No significant changes in the Bcl-2 or Bcl-XL
protein levels were found in the K562 cells after the apicidin
treatment (data not shown). Increasing amounts of the Bax
protein notably detected in the mitochondrial fraction early after
Fig. 1 Apicidin-induced apoptosis in Bcr-Abl-positive leukemia cells. A, proliferating K562 cells (2  106/ml) were exposed to the designated
concentrations of apicidin for the indicated times, after which the percentage of apoptotic cells was determined by flow cytometric analysis, as
described in “Materials and Methods.” The data are expressed as a mean value of the percentage of apoptotic cells from three independent experiments
performed in duplicate. B, the K562 cells were exposed to 2.5 M apicidin up to 72 h, after which the total genomic DNA was extracted and resolved
on 1.5% agarose gel. The apoptotic DNA fragmentation was visualized by ethidium bromide staining and photographed under UV illumination. Lane
M, DNA marker. C, at the indicated time points after treatment with 2.5 M apicidin, the cells were harvested and fixed in 70% ethanol. After staining
with PI, the apoptotic DNA content was analyzed by flow cytometry. The number of apoptotic cells in the sub-G1 fraction is expressed as a percentage
of the total number of cells. D, primary leukemic blasts (2  106/well) obtained from 4 patients with CML in blast crisis were exposed to 2.5 M
of apicidin for the indicated times, after which the percentage of apoptotic cells was determined by flow cytometric analysis. The data represents the
means of the four separate experiments performed in duplicate; bars, SD.
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8 h of apicidin treatment (Fig. 3C). The cytosolic Bax protein
level decreased after 16 h of apicidin treatment.
Processing of Caspase-3, -8, and -9 by Apicidin. The
processing of the caspase cascades was investigated. As shown
in Fig. 4A, incubation of the K562 cells (2–72 h) with 2.5 M of
apicidin resulted in the proteolytic cleavage of procaspase-3 to
an active Mr 19,000 cleaved product. This indicated that the
effector caspase-3 was activated during apicidin-induced apo-
ptosis. The procaspase-3 cleavage was demonstrated after 24 h
of treatment. The increased levels of cleaved PARP (Mr 89,000
and Mr 24,000) were observed in proportion to the processing of
caspase-3 (Fig. 4A). To confirm the involvement of caspase-3 in
apicidin-induced apoptosis, the effect of DEVD-CHO, a
caspase-3 inhibitor, on the apicidin-induced apoptosis, and the
cleavage of PARP and procaspase-3 was examined. As shown in
Fig. 4B, pretreatment the K562 cells with 50 M of DEVD-CHO
for 2 h completely inhibited the apicidin-induced apoptosis as
well as the cleavage of procaspase-3 and PARP. This indicates
that apicidin induces the apoptosis of K562 cells in a caspase-
dependent manner. As shown in Fig. 4A, the cleavage of pro-
caspase-9 into the Mr 35,000 product was induced by apicidin
concomitantly with that of procaspase-8 and -3. Pretreatment of
the K562 cells with 100 M of the caspase-9 inhibitor LEHD-
fmk abrogated the apicidin-induced processing of caspase-9, -3,
-8, and PARP (Fig. 5).
Apicidin-Induced Apoptosis Occurs Independently of
Fas Receptor System. As shown in Fig. 6A, both the Fas
receptor and the Fas ligand expression levels were unchanged in
the K562 cells after being treated with 2.5 M apicidin. In
addition, it was found that preincubation with 0.6 g/ml of the
Fas-blocking NOK-1 monoclonal antibody for 2 h did not block
the apicidin-induced apoptosis and caspase-3 activation in the
K562 cells (Fig. 6B).
Down-Regulation of p210 Bcr-Abl Protein during Api-
cidin-Induced Apoptosis. The changes in the level of the
Bcr-Abl molecule after treatment with 2.5 M apicidin treatment
were evaluated because apicidin induced apoptosis in the Bcr-
Abl-positive leukemia cells. As shown in Fig. 7A, the p210
Bcr-Abl protein levels were reduced after 16 h of apicidin
treatment, with a near complete loss of the Bcr-Abl protein after
48 h of apicdin treatment. Bcr-Abl mRNA expression was also
examined in the treated cells. The RT-PCR assay demonstrated
that the Bcr-Abl mRNA (305 bp) expression level was also
reduced after the apicidin treatment in a time-dependent manner
(Fig. 7B).
DISCUSSION
This study demonstrated that apicidin induces apoptosis in
human Bcr-Abl-expressing leukemia cells, including the pri-
mary leukemic blasts obtained from CML patients in blast crisis,
in a time- and concentration-dependent manner. The K562 cells
exposed to apicidin demonstrated a dramatic increase in the
mitochondrial dysfunction (e.g., loss of MMP and cytosolic
cytochrome c release) associated with the activation of the
caspase cascades, PARP cleavage, and the appearance of the
characteristic morphological features of apoptosis.
Accumulating evidence suggests that the inhibition of
histone deacetylation is closely related to the induction of
apoptosis in various cancer cells, including APL (23) and my-
elomonocytic leukemia (24, 25). We found that, using acety-
lated histone type-specific antibody, acetylated histone H4 ac-
cumulated in the K562 cells shortly after the apicidin treatment.
However, the timing of cell death caused by the apicidin did not
exactly correlate with the HDAC inhibitory effects. There was a
notable time lag between the initiation of the increase in the
acetylated histone H4 levels and the induction of apoptosis in
the K562 cells. In addition, the extent of HDAC inhibition and
apoptosis were not closely correlated. The phenotype induced
by the HDAC inhibitors, e.g., apoptosis, appears to be related to
the intrinsic characteristics of the particular transformed cell line
rather than to the extent of HDAC inhibition itself (17). It was
reported that sodium butyrate and trichostatin readily induced
apoptosis in the human IL-2-dependent ILT-Mat leukemia cells,
whereas they induced far less apoptosis in the K562 cells (34).
However, these inhibitors similarly increased the acetylation
levels of histone in both cell types (34). The present data suggest
that histone hyperacetylation alone does not account for the
apoptotic effect, and different mechanisms other than histone
acetylation could be involved in the HDAC inhibitor-mediated
apoptosis in Bcr-Abl-positive leukemia cells.
Two pathways of caspase activation for the induction of
apoptosis were identified. The first begins at the death receptors
such as Fas (35). When a Fas ligand binds to the Fas death
receptor, the adaptor molecule, FADD, is recruited to the recep-
tor. This allows the binding and proteolysis of procaspase-8,
which generates activated caspase-8 (36–38). The activated
caspase-8 then processes the effector caspases (caspase-3, -6,
and -7) for activation (35, 39, 40). In the second pathway,
diverse proapoptotic signals converge at the mitochondrial level,
inducing the translocation of cytochrome c into the cytosol.
Cytochrome c triggers caspase-9 activation initiating a down-
stream caspase cascade through the complex formation with
Apaf-1, dATP, and pro-caspase-9 in the cytosol, which ulti-
mately leading to the activation of the executioner caspase-3 and
Fig. 2 Effect of apicidin on the acetylation of histone H4 in K562 cells.
The K562 cells were either exposed to various apicidin concentrations
for 24 h (A) or treated with 2.5 M apicidin for the indicated times (B).
The histone fractions were isolated, and 10 g of the protein were run
on 15% SDS-PAGE gel, blotted, and probed with antibodies against
acetylated histone H4 and -tubulin, which served as an internal control.
In addition, the histone H4 expression level in the cell lysate was
examined by Western blot analysis using anti-histone H4 antibody. c,
control (0.1% DMSO-treated) cells.
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finally cell death (39–44). In this study, the release of cyto-
chrome c into the cytosol was demonstrated shortly after being
exposed to apicidin, with maximum levels being observed after
16 h of treatment. The degree of MMP disruption correlated
with the release of cytochrome c. The release of cytochrome c
was followed by the processing of caspase-3, -8, and -9, indi-
cating that the cytochrome c release is a preceding event for the
activation of the caspase cascades. Pretreating the K562 cells
with a caspase-3 inhibitor completely inhibited the apicidin-
induced apoptosis, indicating that the apoptosis process was
caspase-dependent.
The processing of caspase-8, -9, and -3, and PARP cleav-
Fig. 3 Apicidin induces the mitochondrial membrane damage. A, K562 cells were exposed to 2.5 M of apicidin for the indicated times, after which
the loss of the mitochondrial membrane potential (  m) was assessed in the DiOC6-treated specimens by flow cytometry, as described in “Materials
and Methods.” The values are expressed as the mean percentage of cells exhibiting a low MMP, as reflected by reduced levels of DiOC6 uptake; bars,
SD. Effect of apicidin on the cytochrome c release (B) and Bax translocation (C). The K562 cells were treated with 2.5 M of apicidin for the
indicated times, after which the cytosolic and mitochondrial fractions were prepared as described in “Materials and Methods” and separated by
SDS-PAGE. Equal amounts of the protein (20 g) from the cytosolic and mitochondrial fractions were analyzed by Western blotting using antibodies
against cytochrome c and Bax, respectively. The results of a representative study are shown; two additional experiments produced equivalent results.
Fig. 4 Apicidin-induced processing of caspase-8, -9, -3, and PARP. A, the K562 cells were exposed to 2.5 M of apicidin for the indicated times,
after which the protein fractions were subjected to Western blot analysis. After separation on SDS-PAGE, the blots were probed with antibodies
against procaspase-8, cleaved caspase-8, procaspase-9, cleaved caspase-9, procaspse-3, cleaved caspase-3, and PARP. Each lane was loaded with 20
g of protein, and after analysis, the blots were stripped and reproved for -tubulin to ensure an equal loading and protein transfer. The results of
a representative study are shown; two additional experiments produced equivalent results. B, effect of caspase-3 inhibitor on the apicidin-induced
apoptosis and processing of caspases. The K562 cells were pretreated with 50 M of the caspase-3 inhibitor DEVD-CHO for 2 h and then treated with
2.5 M apicidin for 48 h. The processing of procaspase-3 or PARP was examined by Western blot analysis. The mean value of the percentage of
apoptotic cells determined by flow cytometry is shown in the bottom line.
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age was detectable after 24 h of apicidin treatment, when the
apoptotic cell population and DNA laddering were obvious,
albeit only modest, and the maximum levels of H4 acetylation
was observed. We observed that the expression levels of both
the Fas receptor and the Fas ligand remained unchanged in the
K562 cells after the apicidin treatment. It was also found that
pretreating the K562 cells with NOK-1 anti-Fas blocking anti-
body did not block either the apicidin-induced apoptosis or
procaspase-3 cleavage. However, in the HL-60 cells, the Fas
signaling pathway was directly involved in apicidin-mediated
apoptosis (32). The effect and mechanism of the HDAC inhib-
itors on the induction of apoptosis can differ according to the
tumor cells and types of HDAC inhibitors. Considering these
results, processing of caspase-8 by apicidin was not directly
associated with the activation of the Fas/FasL death receptor
signaling pathway in Bcr-Abl-positive K562 cells. This study
found that pretreating the K562 cells with a specific caspase-9
LEHD-fmk inhibited the apicidin-induced activation of
caspase-3, -8, and the induction of apoptosis. These findings
favor a model where both caspase-3 and caspase-8 are activated
by a common preceding event, i.e. mitochondria-dependent
procaspase-9 activation in the apicidin-treated K562 cells.
Bax translocation from the cytosol into the mitochondria
after apoptotic stimulation is believed to be a crucial step for
triggering the release of cytochrome c release from the mito-
chondria and disrupting MMP (45, 46). In the present study, Bax
translocation into the mitochondria preceded the maximum de-
gree of cytochrome c release into the cytosol and remained
elevated thereafter. The increase in the mitochondrial Bax levels
was succeeded by a decrease in the cytosolic Bax protein levels.
It was reported recently that the sphingolipid metabolite phyto-
sphingosine induced the mitochondrial translocation of Bax
without changing the Bax protein levels in the cancer cell lines
(47). This suggests that an intracellular process involved in the
transmembrane localization of the Bax protein can differ ac-
cording to the cell types as well as the apoptosis-inducing
agents. Because there was no p53 protein expression in the
K562 cells in this study (data not shown), the apicidin-induced
Bax translocation can be considered to be p53-independent.
Because the high Bcr-Abl expression level prevents the trans-
location of cytosolic Bax and the release of cytochrome c into
the cytosol (48), the prominent increase in the amounts of Bax
translocation and cytochrome c released into the cytosol might
Fig. 5 Effect of caspase-9 inhibitor on the apicidin-induced processing
of caspases. The K562 cells were pretreated with 100 M of caspase-9
inhibitor LEHD-fmk for 2 h, followed by 2.5 M apicidin treatment for
an additional 48 h. The cleavage of procaspase-8, -3, -9, and PARP was
examined by Western blot analysis using the corresponding antibodies.
The results of a representative study are shown; two additional experi-
ments yielded similar results.
Fig. 6 Apicidin-induced apoptosis in K562 cells is independent of the
Fas-Fas ligand pathway. A, after treating the K562 cells with 2.5 M of
apicidin for the indicated times, the expression of Fas and the Fas ligand
were examined by Western blot analysis using the appropriate antibod-
ies. B, the cells were pretreated with 0.6 g/ml anti-Fas blocking
NOK-1 antibodies for 2 h, which was followed by a treatment with 2.5
M apicidin for an additional 48 h. The cleavage of procaspase-3 was
examined by Western blot analysis. The mean value of the percentage of
apoptotic cells determined by flow cytometry is shown in the bottom
line.
Fig. 7 Effect of apicidin on the Bcr-Abl protein and mRNA expres-
sion. A, after treating the K562 cells with 2.5 M apicidin for the
indicated times, the p210 Bcr-Abl protein expression was examined by
Western blot analysis using c-Abl antibody. Each lane was loaded with
20 g of protein; the blots were subsequently stripped and reproved for
the expression of -tubulin to ensure the equivalent loading and transfer.
B, the Bcr-Abl mRNA expression level was simultaneously determined
by RT-PCR, as described in “Materials and Methods.” The RT-PCR
assay demonstrated that the Bcr-Abl mRNA (305 bp) expression level
decreased after the apicidin treatment in a time-dependent manner.
	2-Microglobulin was used as the loading control.
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be closely associated with the down-regulation of the Bcr-Abl
protein.
The K562 cell line displays a relatively high level of
resistance to most cytotoxic drugs, which is probably because
of a combination of Bcr-Abl oncogene expression (26, 49 –
51). The resistance to chemotherapeutic agent-induced apo-
ptosis in the K562 cells is known to be associated with the
inhibition of MMP collapse and the release of cytochrome c,
which prevents the activation of the downstream caspases
and apoptosis (50, 52, 53). In addition to the upstream block,
it was also found that the K562 cells were resistant to the
cytochrome c-induced activation of caspase-9 and -3 (54, 55).
Because apicidin effectively induced apoptosis in the K562
cells, it is possible that the down-regulation of the p210
Bcr-Abl protein might have taken place during the process of
apoptosis. In this study, the Bcr-Abl protein levels reduced
considerably after 16 h of apicidin treatment, with a near
complete loss after 48 h. The down-regulation of Bcr-Abl
correlated with the increase in the cytosolic cytochrome c
levels, the extent of Bax translocation, the extent of MMP
disruption, the activation of the caspase cascade, and the
amount of apoptosis in the K562 cells.
RT-PCR analysis demonstrated that the Bcr-Abl mRNA
expression levels also decreased significantly after the api-
cidin treatment. This suggests that apicidin down-regulates
the Bcr-Abl molecule at the transcriptional level, although
another mechanism, e.g., proteasomal- or caspase-dependent
protein degradation, might also be involved in this process.
Usually, the HDAC inhibitors can induce transcriptional ac-
tivation of a number of genes (6, 7, 14, 24, 32). However, the
HDAC inhibitors can also down-regulate the transcription of
certain genes. Sodium butyrate and trichostatin abrogated the
IL-2-mediated gene expression in the IL-2-dependent leuke-
mia cell line (34). FK228 inhibits the induction and activity
of hypoxia-inducible factor-1 and the vascular endothelial
growth factor in response to hypoxia (56). FR901228 inhibits
catalytic subunit of telomerase mRNA expression in the
small-cell lung cancer cell lines (57). It was reported recently
that suberoylanilide hydroxamic acid, a HDAC inhibitor, also
reduce the level of Bcr-Abl mRNA (58). This suggests that
the HDAC inhibitors can down-regulate the transcription of
specific genes in various cancer cells. However, the mecha-
nisms responsible for the transcriptional down-regulation of
these genes have not been defined. Although the precise
mechanism by which apicidin down-regulates the Bcr-Abl
transcript remains to be clarified, this study suggests that the
Bcr-Abl mRNA down-regulation contributes, at least in a
part, to the apicidin-induced apoptosis in K562 cells.
These results suggest that the HDAC inhibitor apicidin
effectively induces the apoptosis of human Bcr-Abl-positive
leukemia cells via the activation of the mitochondrial path-
way-dependent caspase cascades. Although the amount of
histone H4 acetylation was increased significantly as a result
of the apicidin treatment, its direct contribution to apoptosis
in the K562 cells was not plausible. The down-regulation of
Bcr-Abl mRNA may be one of the important mechanisms
involved in the apicidin-mediated apoptosis in the K562
cells. This experimental study provides the rationale to ad-
ditionally investigate apicidin as a potential therapeutic agent
for Bcr-Abl-positive leukemia cells.
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